Chi-Med's Surufatinib, Generic Ibrance Among Latest China Approvals
Large Batch Of Late 2020 Nods
Executive Summary
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.